Education
About Us
Working with TipRanks
Follow Us
Evolus Inc (EOLS)
NASDAQ:EOLS
EOLS Stock Chart & Stats
$4.13
-$0.47(-4.38%)
At close: 4:00 PM EST
$4.13
-$0.47(-4.38%)
Day’s Range― - ―
52-Week Range$4.09 - $14.60
Previous CloseN/A
Volume344.54K
Average Volume (3M)822.89K
Market Cap
$267.71M
Enterprise Value$384.14M
Total Cash (Recent Filing)$53.83M
Total Debt (Recent Filing)$146.10M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
May 12, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding64,819,786
10 Day Avg. Volume475,238
30 Day Avg. Volume822,890
Financial Highlights & Ratios
PEG Ratio6.72
Price to Book (P/B)-18.55
Price to Sales (P/S)1.45
P/FCF Ratio-9.38
Enterprise Value/Market Cap1.43
Enterprise Value/Revenue1.30
Enterprise Value/Gross Profit1.95
Enterprise Value/Ebitda-16.61
Forecast
1Y Price Target
$14.50Price Target Upside251.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.17
Revenue Forecast (FY)$330.24M
Bulls Say, Bears Say
Bulls Say
Financial Flexibility And Path To ProfitabilityCash on hand and access to debt facilities without restrictive covenants provide financial flexibility while management targets sustainable annual profitability, underpinning investor confidence.
Market Share ExpansionCompany expanded market share in a weak aesthetic market by aligning its sales approach with injectors and offering a product that delivers consistent clinical results, supporting stronger competitive positioning.
New Product Launch And BundlingCommercial rollout of new injectable fillers combined with a bundling program reduces competitors' advantages and is positioned to win additional customer accounts and diversify revenue streams.
Bears Say
Macroeconomic And Consumer Spending HeadwindsPersistent macroeconomic pressures and weak consumer sentiment are constraining discretionary spending on aesthetic treatments, weighing on toxin and filler growth.
Near-term Sales Momentum UncertaintyNear-term guidance implies revenue growth similar to prior periods, prompting analysts to maintain cautious ratings while awaiting clearer signs of a market turnaround.
Reduced Long-term OutlookCompany reduced its long-term financial outlook and lowered revenue expectations, resetting investor growth assumptions and increasing execution risk.
Evolus News
EOLS FAQ
What was Evolus Inc’s price range in the past 12 months?
Evolus Inc lowest stock price was $4.09 and its highest was $14.60 in the past 12 months.
What is Evolus Inc’s market cap?
Evolus Inc’s market cap is $267.71M.
When is Evolus Inc’s upcoming earnings report date?
Evolus Inc’s upcoming earnings report date is May 12, 2026 which is in 69 days.
How were Evolus Inc’s earnings last quarter?
Evolus Inc released its earnings results on Mar 03, 2026. The company reported $0.044 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.014.
Is Evolus Inc overvalued?
According to Wall Street analysts Evolus Inc’s price is currently Undervalued.
Does Evolus Inc pay dividends?
Evolus Inc does not currently pay dividends.
What is Evolus Inc’s EPS estimate?
Evolus Inc’s EPS estimate is -0.12.
How many shares outstanding does Evolus Inc have?
Evolus Inc has 64,819,786 shares outstanding.
What happened to Evolus Inc’s price movement after its last earnings report?
Evolus Inc reported an EPS of $0.044 in its last earnings report, beating expectations of $0.03. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Evolus Inc?
Currently, no hedge funds are holding shares in EOLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.50 (251.09% Upside)
$14.50 (251.09% Upside)
Blogger Sentiment
Bullish
EOLS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 424.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Very Bullish
Bullish news 83%
Bearish news 17%
Bearish news 17%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.59%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.62%
Trailing 12-Months
Company Description
Evolus Inc
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
EOLS Company Deck
EOLS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong growth in consumer engagement, successful product launches, and international expansion, despite facing macroeconomic challenges and tariff uncertainties. Evolus demonstrates resilience and strategic adaptation, positioning for continued growth.View all EOLS earnings summariesEOLS Stock 12 Month Forecast
Average Price Target
$14.50
▲(251.09% Upside)
Technical Analysis
Emergent Biosolutions
―
Rockwell Med
―
Organogenesis Holdings
―
Aquestive Therapeutics
―
Journey Medical Corp
―
Ownership Overview
3.24% Insiders
9.06% Mutual Funds
33.13% Other Institutional Investors
43.23% Public Companies and
Individual Investors